Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bloom, J. C.
Right arrow Articles by Morgan, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloom, J. C.
Right arrow Articles by Morgan, D. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Immune System and Disorders
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal Article

The Role of Conventional Pathology and Toxicology in Evaluating the Immimotoxic Potential of Xenobiotics

John C. Bloom

Department of Experimental Pathology, Smith Kline and French Laboratories, P.O. Box 7929, Philadelphia, Pennsylvania 19101

Patricia A. Thiem

Department of Experimental Pathology, Smith Kline and French Laboratories, P.O. Box 7929, Philadelphia, Pennsylvania 19101

D. Gwyn Morgan

Department of Experimental Pathology, Smith Kline and French Laboratories, P.O. Box 7929, Philadelphia, Pennsylvania 19101

Investigating the immunotoxic potential of candidate drugs as part of a preclinical safety evaluation poses several problems. These include the need for practical, validated tests, the difficulty in establishing the toxicologic significance of positive findings, and a poor understanding of the predictive value such findings hold for drug effects in man. A key component of this investigation is the toxicologic profile generated through preclinical toxicity and safety studies. As this "routine" assessment becomes increasingly comprehensive and sophisticated, most toxicologically significant drug-associated effects are revealed. Such findings may serve as "triggers" for investigating possible immune mechanisms. Decisions to test specifically for immunotoxicity may also be influenced by the molecular structure and pharmacologic profile of the compound, as well as the intended use of the drug. Examples of such indications and follow–up studies are discussed in this review. We are presently poorly equipped to effectively screen drugs indiscriminately for an immunotoxic potential. We are better prepared, however, to investigate whether a drug-associated change is due to an adverse effect on the immune system. This problem-oriented approach to immunotoxicology challenges us as diagnosticians and immunopathologists, and requires a close working relationship among the toxicologic pathologist, the basic immunologist, the immunopharmacologist, and the clinician.

  • 1. Babior BM, Bigbee JW, and Bigbee JW (1973). Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J. Clin. Invest. 52: 741–744.[Web of Science][Medline] [Order article via Infotrieve]
  • 2. Bank NU, and Bigbee JW (1983). Hematologic complications associated with β-lactam antibiotics. Rev. Infect. Dis. 5(Suppl. 2): S380–S383.
  • 3. Bekesi JH, Bigbee JW, Bigbee JW, Bigbee JW, Bigbee JW, Bigbee JW, and Bigbee JW (1979). Immunologic dysfunction among PBB-exposed Michigan farmers. In: Health effects of halogenated aromatic hydrocarbons. Ann. N.Y. Acad. Sci. 320: 717–728.[Medline] [Order article via Infotrieve]
  • 4. Bloom JC, Bigbee JW, Bigbee JW, Bigbee JW, and Bigbee JW (1985). Gold-induced immune thrombocytopenia in the dog. Vet. Pathol. 22: 492–499.[Abstract]
  • 5. Bloom JC, Bigbee JW, Bigbee JW, Bigbee JW, and Bigbee JW (1985). Cephalosporin-induced immune cytopenia in the dog–-Demonstration of cell-associated antibodies. Blood 66: 1232.
  • 6. Claman H (1972). Corticosteroids and lymphoid cells. N. Engl. J. Med. 287: 388–397.[Web of Science][Medline] [Order article via Infotrieve]
  • 7. Davies GE (1983). Uses and limitations of models for predicting hypersensitivity. In: Immunotoxicology, GG Gibson, R Hubbard, and DV Parke (eds). Academic Press, New York, pp. 125–130.
  • 8. Davis P, Bigbee JW, and Bigbee JW (1979). In vivo and in vitro effects of gold salts on lymphocyte transformation responses and antibody dependent cell-mediated cytotoxicity. J. Rheumatol. 6: 527–533.[Web of Science][Medline] [Order article via Infotrieve]
  • 9. Davis P, and Bigbee JW (1982). Effect of gold salts on polymorphonuclear leukocyte function. In: Auranofin in Rheumatoid Arthritis. Workshop Proceedings, 15th International Congress of Rheumatology, Acad. Prof. Servs., New York, p. 19.
  • 10. Deldar A, Bigbee JW, Bigbee JW, and Bigbee JW (1985). The ultrastructural changes in canine bone marrow following cephalosporin therapy. Blood 66: 1202.[Abstract/Free Full Text]
  • 11. Deldar A, Bigbee JW, Bigbee JW, Bigbee JW, and Bigbee JW (1985). Residual stem cell defects associated with cephalosporin therapy in dogs. Blood 66: 1202.[Abstract/Free Full Text]
  • 12. deWeck AL (1983). Immunopathological mechanisms and clinical aspects of allergic reactions to drugs. In: Handbook of Experimental Pharmacology, Vol. 63: Allergic Reactions to Drugs, AL deWeck and H Bundgaard (eds). Springer-Verlag, New York, pp. 75–133.
  • 13. deWeck AL (1983). Prevention and treatment of drug allergies. In: Handbook of Experimental Pharmacology. Vol. 63: Allergic Reactions to Drugs, AL deWeek and H. Bundgaard (eds). Springer-Verlag, New York, pp. 227–240.
  • 14. DiMartino MJ, and Bigbee JW (1980). Effect of auranofin on antibody-dependent cellular cytotoxicity (ADCC) mediated by rat peripheral blood polymorphonuclear leukocytes and mononuclear cells. Inflammation 4: 279–288.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 15. Exon JH, Bigbee JW, Bigbee JW, and Bigbee JW (1984). Multiple immunoassay in a single animal: A practical approach to immunotoxicologic testing. Fund. Appl. Toxicol. 4: 278–283.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 16. Fahey JL, and Bigbee JW (1965). Quantitative determination of serum immunoglobulins in antibody-agar plates. J. Immunol. 94: 84–90.[Abstract/Free Full Text]
  • 17. Felsburg PJ, Bigbee JW, and Bigbee JW (1980). A rapid microtechnique for in vitro stimulation of canine lymphocytes using whole blood. Vet. Immunol. Immunopathol. 1: 251–261.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 18. Felsburg PJ, Bigbee JW, Bigbee JW, and Bigbee JW (1983). Potentiation of the canine lymphocyte blastogenic response by indomethacin. Vet. Immunol. Immunopathol. 4: 533–543.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 19. Finkelstein AE, Bigbee JW, Bigbee JW, and Bigbee JW (1982). Auranofin and lysosomal enzymes. J. Rheumatol. 9(Suppl. 8): 46–53.[Web of Science][Medline] [Order article via Infotrieve]
  • 20. Goodwin JS, and Bigbee JW (1980). Regulation of the immune response by prostaglandins. Clin. Immunol. Immunopathol. 15: 106–122.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 21. Gordon D, and Bigbee JW (1984). Effects of piroxicam on mononuclear cells. Comparison with other antiarthritic drugs. Inflammation 8: S87–S102.[CrossRef][Medline] [Order article via Infotrieve]
  • 22. Griswold DE, Bigbee JW, Bigbee JW, and Bigbee JW (1985). Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. J. Rheumatol. 12: 490–497.[Web of Science][Medline] [Order article via Infotrieve]
  • 23. Hanna N, DiMartino M, Griswold DE, and Poste G. (1983). Immunology of auranofin–-An overview. Excerpta Medica, Current Clinical Practice Series 7: 60–70.
  • 24. Harth M, Bigbee JW, and Bigbee JW (1983). Cells with immunoregulatory function: The human macrophages and the effects of remittive drugs. J. Rheumatol. 12: 76–80.
  • 25. Harth M, Bigbee JW, and Bigbee JW (1983). Monocyte dependent excited oxygen radical generation in rheumatoid arthritis: Inhibition by gold sodium thiomalate. J. Rheumatol. 10: 701–707.[Web of Science][Medline] [Order article via Infotrieve]
  • 26. Hurst NP, Bigbee JW, and Bigbee JW (1986). Studies of the effect of D-penicillamine and sodium aurothio-malate therapy on superoxide anion production by monocytes from patients with rheumatoid arthritis: Evidence for in vivo stimulation of monocytes. Annals Rheum. Dis. 45: 37–43.[Abstract/Free Full Text]
  • 27. Hutchings P, Bigbee JW, and Bigbee JW (1985). Effects of low doses of cyclophosphamide and low doses of irradiation on the regulation of induced erythrocyte autoantibodies in mice. Immunology 54: 97–104.[Web of Science][Medline] [Order article via Infotrieve]
  • 28. Huy DP, Roch-Arveiller M, Bigbee JW, and Bigbee JW (1985). In vitro and in vivo effects of gold salts on Chemotaxis and random migration of rat polymorphonuclear leukocytes. Agents Actions 16: 363–368.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 29. Kociba RJ (1981). Morphologic considerations in the detection of immune suppression in routine toxicity studies. In: Immunologic Considerations in Toxicology, Vol. 2, RP Sharma (ed). CRC Press, Boca Raton, pp. 123–132.
  • 30. Lee JC, Bigbee JW, Bigbee JW, and Bigbee JW (1985). Suppressed IL-2 production and response in AA rats: Role of suppressor cells and the effect of auranofin treatment. J. Rheumatol. 12: 885–891.[Web of Science][Medline] [Order article via Infotrieve]
  • 31. Lewis AJ, Bigbee JW, and Bigbee JW (1982). Therapeutic modulation of cell mediated immunity. Ann. Rev. Med. Chem. 17: 191–202.[CrossRef]
  • 32. Lipsky PE, and Bigbee JW (1977). Inhibition of antigenand mitogen-induced lymphocyte proliferation by gold compounds. J. Clin. Invest. 59: 455–466.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 33. Littman BE, and Bigbee JW (1985). Effects of gold sodium thiomalate on functional correlates of human monocyte maturation. Arthritis Rheum. 28: 1384–1392.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 34. Lorber A, Bigbee JW, and Bigbee JW (1982). Effects of chrysotherapy on cell mediated immune response. J. Rheumatol. 9(Suppl. 8): 37–45.[Web of Science]
  • 35. Maclouf J, Bigbee JW, Bigbee JW, and Bigbee JW (1976). 125I derivatives of prostaglandins. A novel approach in prostaglandin analysis by radioimmunoassay. Biochim. Biophys. Acta 431: 139–146.[Medline] [Order article via Infotrieve]
  • 36. McIntosh J, Bigbee JW, Bigbee JW, and Bigbee JW (1976). Defective immune and phagocytic functions in uremia and renal transplantation. Int. Arch. Allergy Appl. Immun. 51: 544–559.[Web of Science][Medline] [Order article via Infotrieve]
  • 37. Norbury KC (1985). Immunotoxicological evaluation: an overview. J. Amer. Coll. Toxicol. 4: 279–290.[Web of Science]
  • 38. Palacios R and Alarcon-Segovia D (1981). Cimetidine abrogates suppressor T cell function in vitro. Immunol. Letters 3: 33–37.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 39. Palmblad J, Bigbee JW, and Bigbee JW (1982). Modulation of neutrophil functions by auranofin. Int. J. Immunopharmacol. 4: 310.
  • 40. Pantazis CG, and Bigbee JW (1979). Assessment of blood leukocyte microbial killing by using a new fluorochrome microassay. J. Reticuloendothel. Soc. 26: 155–170.[Web of Science][Medline] [Order article via Infotrieve]
  • 41. Parke AL (1983). Clinical manifestations of drug-induced syndromes. In: Immunotoxicology, GG Gibson, R Hubbard, and DV Parke (eds). Academic Press, New York, pp. 27–40.
  • 42. Payne BJ (ed) (1978). The toxicity of three gold-containing compounds in laboratory animals. Vet. Pathol. 15: 1–100.[Abstract]
  • 43. Perlman P, and Bigbee JW (1969). Cytotoxic effect of lymphoid cells in vitro. Adv. Immunol. 11: 117–193.[Medline] [Order article via Infotrieve]
  • 44. Pocchiari F, Bigbee JW, and Bigbee JW (1979). Human health effects from accidental release of tetrachlorodibenzo-p-dioxin (TCDD) at Seveso, Italy. Ann. N.Y. Acad. Sci. 320: 311–320.[Medline] [Order article via Infotrieve]
  • 45. Roisman FR, Bigbee JW, and Bigbee JW (1983). Superoxide radical production by human leukocytes exposed to immune complexes: Inhibitory action of gold compounds. Inflammation 7: 355–362.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 46. Roisman FR, Bigbee JW, and Bigbee JW (1982). Inhibitory action of auranofin on superoxide production by phagocytic cells and blockade of inhibition by thiol protecting agents. Arthritis Rheum. 25: S130.
  • 47. Russell AS, Bigbee JW, and Bigbee JW (1982). The effect of a new antirheumatic drug, triethylphosphine gold (auranofin) on in vitro lymphocyte and monocyte cytotoxicity. J. Rheumatol. 9: 30–35.[Web of Science][Medline] [Order article via Infotrieve]
  • 48. Salmeron G, and Bigbee JW (1982). Modulation of human immune responsiveness in vitro by auranofin. J. Rheumatol. 9(Suppl. 8): 25–31.[Web of Science][Medline] [Order article via Infotrieve]
  • 49. Samter M, and Bigbee JW (1978). Immunological Diseases, Vol. I and II. 3rd ed. Little, Brown and Co., Boston.
  • 50. Scheinberg MA, Bigbee JW, and Bigbee JW (1982). The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J. Rheumatol. 9: 366–369.[Web of Science][Medline] [Order article via Infotrieve]
  • 51. Schmidt RR (1984). Altered development of immunocompetence following prenatal or combined prenatal-postnatal insult: A timely review. J. Amer. Coll. Toxicol. 3: 57–72.[Web of Science]
  • 52. Simon PL, Bigbee JW, and Bigbee JW (1985). A modified assay for interleukin-1 (IL-1). J. Immunol. Methods 84: 85–94.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 53. Slauson DO, and Bigbee JW (1982). Mechanisms of Disease: A Textbook of Comparative General Pathology. Williams and Wilkins, Baltimore.
  • 54. Smith MD, Bigbee JW, Bigbee JW, and Bigbee JW (1979). Cimetidine and the immune response. Lancet i: 1406–1407.
  • 55. Symoens J, and Bigbee JW (1977). Levamisole in the modulation of the immune response: The current experimental and clinical state. J. Reticuloendothel. Soc. 21: 175–221.[Web of Science][Medline] [Order article via Infotrieve]
  • 56. Thiem P, Bigbee JW, and Bigbee JW (1986). Techniques for assessing canine mononuclear function in the investigative toxicology laboratory. The Toxicologist 6: 64.
  • 57. Thompson RL, and Bigbee JW (1983). Cephalosporin antibiotics Mayo Clin. Proc. 58: 79–87.[Web of Science][Medline] [Order article via Infotrieve]
  • 58. Tizard IR (1982). An Introduction to Veterinary Immunology, 2nd ed. Saunders, Philadelphia.
  • 59. Ugai K, Bigbee JW, and Bigbee JW (1979). Gold-induced changes in the morphology and functional capabilities of human monocytes. Arthritis Rheum. 22: 1352–1360.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 60. Vos JG (1981). Screening and function studies in immunotoxicity testing. Vet. Quarterly 3: 190–195.
  • 61. Wachsmuth ED (1983). Evaluating immunopathological effects of new drugs. In: Immunotoxicology, GG Gibson, R Hubbard, and DV Parke (eds). Academic Press, New York, pp. 237–250.
  • 62. Walz DT, Bigbee JW, Bigbee JW, Bigbee JW, and Bigbee JW (1983). Biologic actions and pharmacokinetic studies of auranofin. Amer. J. Med. 75: 90–108.[Web of Science][Medline] [Order article via Infotrieve]
  • 63. Ward AM, Bigbee JW, Bigbee JW, Bigbee JW, and Bigbee JW (1976). Immunological mechanisms in the pathogenesis of vinyl chloride disease. Brit. Med. J. I: 939–938.
  • 64. Winkelstein A (1984). Immune suppression resulting from various cytotoxic agents. Clin. Immunol. Allerg. 4: 295–315.
  • 65. Wright DH (1982). Immunological aspects of diagnostic histopathology. In: Clinical Aspects of Immunology, Vol. I, PJ Lachmann and DK Peters (eds). Blackwell Scientific Publications, Oxford, pp. 443–461.

Toxicologic Pathology, Vol. 15, No. 3, 283-293 (1987)
DOI: 10.1177/019262338701500306
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bloom, J. C.
Right arrow Articles by Morgan, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloom, J. C.
Right arrow Articles by Morgan, D. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Immune System and Disorders
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?